When was iPS Portal founded?

iPS Portal was founded in 2014 and raised its 1st funding round 12 years after it was founded.

Where is iPS Portal located?

iPS Portal is headquartered in Kyoto, Japan.

Is iPS Portal a funded company?

iPS Portal is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jan 06, 2026.

When was the latest funding round of iPS Portal?

iPS Portal's latest funding was a $***** Seed round on Mar 11, 2026, with participation from 1 investor. Its primary sector is Biopharma Outsourcing. Globally, the Biopharma Outsourcing sector has seen $1.02B in funding in 2026 to date.

Where does iPS Portal rank among its competitors?

iPS Portal ranks 29th amongst 132 active competitors, of which 27 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was iPS Portal, which secured an undisclosed amount in Mar, 2026.

Who are the top competitors of iPS Portal?

iPS Portal's top competitors include Blue Rock Therapeutics, CellCarta and Invivyd. Among them, iPS Portal secured the most recent funding round in March, 2026.

iPS Portal - 2026 Company Profile, Funding & Competitors

iPS Portal is a seed company based in Kyoto (Japan), founded in 2014. It operates as a Biotechnology company that specializes in iPS cell technology. iPS Portal has raised an undisclosed amount in funding. The company has 132 active competitors, including 27 funded and 13 that have exited. Its top competitors include companies like Blue Rock Therapeutics, CellCarta and Invivyd.

Company Details

Website: ipsportal.com
Social

Key Metrics

Founded Year

2014

Location

Kyoto, Japan

Stage

Seed

Latest Funding Round

Seed, Mar 11, 2026, $*****

Investors

NTT DATA & 1 more

Ranked

29^th among 132 active competitors

Similar Companies

Blue Rock Therapeutics & 139 more

View iPS Portal's full profile

iPS Portal has raised funding over 2 rounds. Its first funding round was on Jan 06, 2026. Its latest funding round was a Seed round on Mar 11, 2026 for $*****. 1 investor participated in its latest round. iPS Portal has 2 institutional investors.

Here is the list of recent funding rounds of iPS Portal:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Mar 11, 2026	3224756	Seed	3137053	5421224	9909231	2371396
Jan 06, 2026	8734103	Seed	7707568	2031208	8076001	NTT DATA

Access funding benchmarks and valuations. Sign up today!

View details of iPS Portal's funding rounds and investors

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of iPS Portal include Blue Rock Therapeutics, CellCarta and Invivyd. Here is the list of Top 10 competitors of iPS Portal, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	62/100
2nd	CellCarta 2002, Montreal (Canada), Acquired	CRO focused on providing histopathology and genomics services	$7.5M	Waters Corporation, Great Point Partners & 5 others	59/100
3rd	Invivyd 2022, Waltham (United States), Public	Provider of drug research & development targets stem cell and clinical trial services	-	Foresite Capital, Premji Invest & 1 others	53/100
4th	Kincell Bio 2023, Gainesville (United States), Series A	Provider of clinical cell therapy development & manufacturing and consulting services	$58M	NewSpring, Kineticos	49/100
5th	GC Green Cross Lab Cell 2008, Yongin si (South Korea), Funding Raised	Provider of research, development, and manufacturing services for cell & gene therapy products	-	-	44/100
6th	XDemics 2017, Monrovia (United States), Series B	CDMO focused on manufacturing cell & viral based therapeutics	$14.8M	-	42/100
7th	Impel Pharmaceuticals 2008, Seattle (United States), Acquired	Provider of trans-formative therapy development and commercialisation services	$67.5M	Norwest, KKR & 4 others	41/100
8th	BioBridge Global 1974, San Antonio (United States), Unfunded	Manufacturer of cell and gene therapy clinical product & testing services	-	-	39/100
9th	Shanghai Cell Therapy Group 2014, Shanghai (China), Series D	Provider of cell-therapy focused research and development services	$202M	CCB International, Jiuzhou Venture Capital ... & 7 others	38/100
10th	Cell Therapies 2003, Melbourne (Australia), Unfunded	Provider of cell and gene therapy clinical product & testing services	-	-	37/100
29th	iPS Portal 2014, Kyoto (Japan), Seed	Biotechnology company that specializes in iPS cell technology	-	NTT DATA, EXEDY	26/100